据报道,甲状腺功能异常和对氯吡格雷的低反应性均与心血管风险增加有关。我们的研究旨在确定接受选择性经皮冠状动脉介入治疗(PCI)的患者中游离三碘甲状腺原氨酸(FT3)与对氯吡格雷的低反应性之间的关系。
连续入选接受择期PCI的患者。所有患者均接受300mg氯吡格雷的负荷剂量,至少12小时后通过血栓弹力图评估血小板功能。对氯吡格雷的低反应性定义为二磷酸腺苷诱导的血小板-纤维蛋白凝块强度>47mm和二磷酸腺苷诱导的血小板抑制率<50%。主要不良心血管事件(MACE)定义为心血管死亡的复合,非致死性心肌梗死,非致命性中风,和缺血驱动的血运重建。
在纳入研究的812名患者中,289显示对氯吡格雷的低反应性。低反应者的FT3水平显着降低(4.61±0.60pmol/l对4.94±4.66pmol/l,p=0.002)。此外,低FT3水平患者的低反应者百分比高于无FT3水平患者(56.1%对34.5%,p=0.007)。Logistic回归分析显示,FT3水平与氯吡格雷低反应性风险独立相关(比值比0.720,95%置信区间[CI]0.533-0.973,p=0.033)。在对氯吡格雷反应性低的患者中,在19个月的中位随访时间,低FT3与MACEs风险增加独立相关(校正后风险比3.040,95%CI1.077-8.580,p=0.036).
在接受择期PCI的患者中,低FT3与氯吡格雷低反应性和心血管事件的风险增加独立相关。
Both thyroid dysfunction and low responsiveness to clopidogrel have been reported to be associated with increased cardiovascular risk. Our study aims at determining the relationship between free triiodothyronine (FT3) and low responsiveness to clopidogrel in patients undergoing elective percutaneous coronary intervention (PCI).
Consecutive patients undergoing elective PCI were enrolled. All patients received a loading dose of 300 mg clopidogrel, and platelet function was assessed by thromboelastography at least 12 h later. Low responsiveness to clopidogrel was defined by an adenosine diphosphate-induced platelet-fibrin clot strength > 47 mm and adenosine diphosphate-induced platelet inhibition rate < 50%. Major adverse cardiovascular events (MACEs) were defined as a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and ischemia-driven revascularization.
Of 812 patients included in the study, 289 showed low responsiveness to clopidogrel. The FT3 level was significantly lower in low responders (4.61 ± 0.60 pmol/l versus 4.94 ± 4.66 pmol/l, p = 0.002). Moreover, the percentage of low responders was greater among patients with low FT3 level than among those without (56.1% versus 34.5%, p = 0.007). Logistic regression analysis showed that a FT3 level was independently associated with the risk of low responsiveness to clopidogrel (odds ratio 0.720, 95% confidence interval [CI] 0.533-0.973, p = 0.033). In patients with low responsiveness to clopidogrel, low FT3 was independently associated with increased risk of MACEs (adjusted hazard ratio 3.040, 95% CI 1.077-8.580, p = 0.036) at a median of 19-month follow-up.
Low FT3 was independently associated with increased risks of both low responsiveness to clopidogrel and cardiovascular events in patients undergoing elective PCI.